APAC水頭症市場-2032年までの産業動向と予測APAC Hydrocephalus Market - Industry Trends and Forecast to 2032 アジア太平洋地域の水頭症市場は、2023年の293,372.44千米ドルから2031年には539,658.18千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は8.1%である。 市場セグメント アジア... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーアジア太平洋地域の水頭症市場は、2023年の293,372.44千米ドルから2031年には539,658.18千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は8.1%である。市場セグメント アジア太平洋地域の水頭症市場:タイプ別(先天性水頭症、後天性水頭症、正常圧水頭症、外水頭症)、診断・治療別(診断と治療)、エンドユーザー別(病院、診療所、診断センター、学術機関・研究機関)、国別(中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、アジア太平洋地域その他)-産業動向と2031年までの予測 アジア太平洋水頭症市場ダイナミクスの概要 促進要因 - 神経疾患の発生率の増加 抑制要因 - 不十分な償還政策 機会 - 医療機関や政府機関による支援の拡大 市場プレイヤー アジア太平洋地域の水頭症市場で事業を展開する主な市場参入企業は以下の通り: - B. Braun傘下のAesculap, Inc. - インテグラ・ライフサイエンス - ジー・サーギウェア - モレール・メディカル社 - アヌンシア社 - クリストフ・ミースケGmbH & co.KG - KARL STORZ SE & Co.KG - 株式会社プロテテス - メドトロニック - ナタス - デスーメディカル - ビカクシラー - シュピーゲルベルグGmbH & Co.KG - ソフィサ - カネカメディックス 目次TABLE OF CONTENTS1 INTRODUCTION 31 1.1 OBJECTIVES OF THE STUDY 31 1.2 MARKET DEFINITION 31 1.3 OVERVIEW OF ASIA PACIFIC HYDROCEPHALUS MARKET 31 1.4 LIMITATIONS 32 1.5 MARKETS COVERED 32 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 TYPE LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 VENDOR SHARE ANALYSIS 44 2.11 SECONDARY SOURCES 45 2.12 ASSUMPTIONS 45 3 EXECUTIVE SUMMARY 46 4 PREMIUM INSIGHTS 48 5 ASIA PACIFIC HYDROCEPHALUS MARKET: REGULATIONS 49 5.1 REGULATIONS IN U.S. 49 5.2 REGULATIONS IN EUROPE 49 5.3 REGULATIONS IN INDIA 49 5.4 REGULATIONS IN JAPAN 50 5.5 REGULATIONS IN BRAZIL 50 6 MARKET OVERVIEW 51 6.1 DRIVERS 53 6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 53 6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 53 6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 54 6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 54 6.2 RESTRAINTS 55 6.2.1 POOR REIMBURSEMENT POLICIES 55 6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 55 6.3 OPPORTUNITIES 56 6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 56 6.3.2 GROWING HEALTHCARE EXPENDITURE 57 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 57 6.4 CHALLENGES 58 6.4.1 HIGH PRODUCT RECALL SCENARIO 58 6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 58 7 ASIA PACIFIC HYDROCEPHALUS MARKET, BY TYPE 59 7.1 OVERVIEW 60 7.2 CONGENITAL HYDROCEPHALUS 63 7.3 ACQUIRED HYDROCEPHALUS 63 7.4 NORMAL-PRESSURE HYDROCEPHALUS 64 7.5 EX-VACUO HYDROCEPHALUS 64 8 ASIA PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 65 8.1 OVERVIEW 66 8.2 DIAGNOSTICS 69 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 69 8.2.2 CT SCAN – HEAD 69 8.2.3 HEAD ULTRASOUND 70 8.3 TREATMENT 70 8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 71 8.3.1.1 HYDROCEPHALUS VALVES 71 8.3.1.2 HYDROCEPHALUS CATHETERS 71 8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 71 8.3.1.2.2 FIX PRESSURE VALVES 72 8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 72 8.3.2.1 PEDIATRIC 72 8.3.2.2 ADULT 72 8.3.3 VENTRICULOSTOMY 72 8.3.4 MEDICATION 72 8.3.5 TREATMENT, BY AGE GROUP 73 8.3.6 INFANTS 73 8.3.7 CHILDREN 73 8.3.8 ADULTS 73 9 ASIA PACIFIC HYDROCEPHALUS MARKET, BY END USERS 74 9.1 OVERVIEW 75 9.2 HOSPITALS 78 9.3 CLINICS 78 9.4 DIAGNOSTIC CENTERS 79 9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 79 9.5.1 HOSPITALS 80 9.5.2 AMBULATORY AND SURGICAL CENTERS 80 9.5.3 HOSPITALS 80 9.5.4 CLINICS 80 9.5.5 DIAGNOSTIC CENTER 81 9.5.6 SURGICAL CENTERS 81 9.5.7 AMBULATORY SURGICAL CENTERS 81 9.5.8 OTHERS 81 10 ASIA PACIFIC HYDROCEPHALUS MARKET, BY REGION 82 10.1 ASIA-PACIFIC 84 10.1.1 JAPAN 89 10.1.2 CHINA 93 10.1.3 SOUTH KOREA 97 10.1.4 INDIA 101 10.1.5 AUSTRALIA 105 10.1.6 SINGAPORE 109 10.1.7 THAILAND 113 10.1.8 MALAYSIA 117 10.1.9 INDONESIA 121 10.1.10 PHILIPPINES 125 10.1.11 VIETNAM 129 10.1.12 REST OF ASIA-PACIFIC 133 11 ASIA PACIFIC HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 134 11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 134 12 SWOT ANALYSIS 135 13 COMPANY PROFILE 136 13.1 MEDTRONIC 136 13.1.1 COMPANY SNAPSHOT 136 13.1.2 REVENUE ANALYSIS 136 13.1.3 COMPANY SHARE ANALYSIS 137 13.1.4 PRODUCT PORTFOLIO 137 13.1.5 RECENT DEVELOPMENTS 137 13.2 AESCULAP, INC. – A B. BRAUN COMPANY 138 13.2.1 COMPANY SNAPSHOT 138 13.2.2 COMPANY SHARE ANALYSIS 138 13.2.3 PRODUCT PORTFOLIO 139 13.2.4 RECENT DEVELOPMENT 139 13.3 INTEGRA LIFESCIENCES 140 13.3.1 COMPANY SNAPSHOT 140 13.3.2 REVENUE ANALYSIS 140 13.3.3 COMPANY SHARE ANALYSIS 141 13.3.4 PRODUCT PORTFOLIO 141 13.3.5 RECENT DEVELOPMENT 142 13.4 SPIEGELBERG GMBH & CO. KG 143 13.4.1 COMPANY SNAPSHOT 143 13.4.2 COMPANY SHARE ANALYSIS 143 13.4.3 PRODUCT PORTFOLIO 144 13.4.4 RECENT DEVELOPMENT 144 13.5 BICAKCILAR 145 13.5.1 COMPANY SNAPSHOT 145 13.5.2 COMPANY SHARE ANALYSIS 145 13.5.3 PRODUCT PORTFOLIO 146 13.5.4 RECENT DEVELOPMENTS 146 13.6 ANUNCIA INC 147 13.6.1 COMPANY SNAPSHOT 147 13.6.2 PRODUCT PORTFOLIO 147 13.6.3 RECENT DEVELOPMENT 147 13.7 CHRISTOPH MIETHKE GMBH & CO. KG 148 13.7.1 COMPANY SNAPSHOT 148 13.7.2 PRODUCT PORTFOLIO 148 13.7.3 RECENT DEVELOPMENT 149 13.8 DESU MEDICAL 150 13.8.1 COMPANY SNAPSHOT 150 13.8.2 PRODUCT PORTFOLIO 150 13.8.3 RECENT DEVELOPMENT 150 13.9 G.SURGIWEAR LTD 151 13.9.1 COMPANY SNAPSHOT 151 13.9.2 PRODUCT PORTFOLIO 151 13.9.3 RECENT DEVELOPMENT 151 13.10 HPBIO 152 13.10.1 COMPANY SNAPSHOT 152 13.10.2 PRODUCT PORTFOLIO 152 13.10.3 RECENT DEVELOPMENT 152 13.11 KANEKA MEDIX CORP 153 13.11.1 COMPANY SNAPSHOT 153 13.11.2 REVENUE ANALYSIS 153 13.11.3 PRODUCT PORTFOLIO 155 13.11.4 RECENT DEVELOPMENTS 155 13.12 KARL STORZ SE & CO. KG 156 13.12.1 COMPANY SNAPSHOT 156 13.12.2 PRODUCT PORTFOLIO 156 13.12.3 RECENT DEVELOPMENT 156 13.13 MÖLLER MEDICAL GMBH 157 13.13.1 COMPANY SNAPSHOT 157 13.13.2 PRODUCT PORTFOLIO 157 13.13.3 RECENT DEVELOPMENT 157 13.14 NATUS MEDICAL INCORPORATED 158 13.14.1 COMPANY SNAPSHOT 158 13.14.2 PRODUCT PORTFOLIO 158 13.14.3 RECENT DEVELOPMENTS 159 13.15 SOPHYSA 160 13.15.1 COMPANY SNAPSHOT 160 13.15.2 PRODUCT PORTFOLIO 160 13.15.3 RECENT DEVELOPMENTS 161 14 QUESTIONNAIRE 162 15 RELATED REPORTS 165
SummaryThe Asia-Pacific hydrocephalus market is expected to reach USD 539,658.18 thousand by 2031 from USD 293,372.44 thousand in 2023, growing with a CAGR of 8.1% in the forecast period of 2024 to 2031. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 31 1.1 OBJECTIVES OF THE STUDY 31 1.2 MARKET DEFINITION 31 1.3 OVERVIEW OF ASIA PACIFIC HYDROCEPHALUS MARKET 31 1.4 LIMITATIONS 32 1.5 MARKETS COVERED 32 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 CURRENCY AND PRICING 37 2.5 DBMR TRIPOD DATA VALIDATION MODEL 38 2.6 MULTIVARIATE MODELLING 41 2.7 TYPE LIFELINE CURVE 41 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 42 2.9 DBMR MARKET POSITION GRID 43 2.10 VENDOR SHARE ANALYSIS 44 2.11 SECONDARY SOURCES 45 2.12 ASSUMPTIONS 45 3 EXECUTIVE SUMMARY 46 4 PREMIUM INSIGHTS 48 5 ASIA PACIFIC HYDROCEPHALUS MARKET: REGULATIONS 49 5.1 REGULATIONS IN U.S. 49 5.2 REGULATIONS IN EUROPE 49 5.3 REGULATIONS IN INDIA 49 5.4 REGULATIONS IN JAPAN 50 5.5 REGULATIONS IN BRAZIL 50 6 MARKET OVERVIEW 51 6.1 DRIVERS 53 6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 53 6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 53 6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 54 6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 54 6.2 RESTRAINTS 55 6.2.1 POOR REIMBURSEMENT POLICIES 55 6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 55 6.3 OPPORTUNITIES 56 6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 56 6.3.2 GROWING HEALTHCARE EXPENDITURE 57 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 57 6.4 CHALLENGES 58 6.4.1 HIGH PRODUCT RECALL SCENARIO 58 6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 58 7 ASIA PACIFIC HYDROCEPHALUS MARKET, BY TYPE 59 7.1 OVERVIEW 60 7.2 CONGENITAL HYDROCEPHALUS 63 7.3 ACQUIRED HYDROCEPHALUS 63 7.4 NORMAL-PRESSURE HYDROCEPHALUS 64 7.5 EX-VACUO HYDROCEPHALUS 64 8 ASIA PACIFIC HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 65 8.1 OVERVIEW 66 8.2 DIAGNOSTICS 69 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 69 8.2.2 CT SCAN – HEAD 69 8.2.3 HEAD ULTRASOUND 70 8.3 TREATMENT 70 8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 71 8.3.1.1 HYDROCEPHALUS VALVES 71 8.3.1.2 HYDROCEPHALUS CATHETERS 71 8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 71 8.3.1.2.2 FIX PRESSURE VALVES 72 8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 72 8.3.2.1 PEDIATRIC 72 8.3.2.2 ADULT 72 8.3.3 VENTRICULOSTOMY 72 8.3.4 MEDICATION 72 8.3.5 TREATMENT, BY AGE GROUP 73 8.3.6 INFANTS 73 8.3.7 CHILDREN 73 8.3.8 ADULTS 73 9 ASIA PACIFIC HYDROCEPHALUS MARKET, BY END USERS 74 9.1 OVERVIEW 75 9.2 HOSPITALS 78 9.3 CLINICS 78 9.4 DIAGNOSTIC CENTERS 79 9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 79 9.5.1 HOSPITALS 80 9.5.2 AMBULATORY AND SURGICAL CENTERS 80 9.5.3 HOSPITALS 80 9.5.4 CLINICS 80 9.5.5 DIAGNOSTIC CENTER 81 9.5.6 SURGICAL CENTERS 81 9.5.7 AMBULATORY SURGICAL CENTERS 81 9.5.8 OTHERS 81 10 ASIA PACIFIC HYDROCEPHALUS MARKET, BY REGION 82 10.1 ASIA-PACIFIC 84 10.1.1 JAPAN 89 10.1.2 CHINA 93 10.1.3 SOUTH KOREA 97 10.1.4 INDIA 101 10.1.5 AUSTRALIA 105 10.1.6 SINGAPORE 109 10.1.7 THAILAND 113 10.1.8 MALAYSIA 117 10.1.9 INDONESIA 121 10.1.10 PHILIPPINES 125 10.1.11 VIETNAM 129 10.1.12 REST OF ASIA-PACIFIC 133 11 ASIA PACIFIC HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 134 11.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 134 12 SWOT ANALYSIS 135 13 COMPANY PROFILE 136 13.1 MEDTRONIC 136 13.1.1 COMPANY SNAPSHOT 136 13.1.2 REVENUE ANALYSIS 136 13.1.3 COMPANY SHARE ANALYSIS 137 13.1.4 PRODUCT PORTFOLIO 137 13.1.5 RECENT DEVELOPMENTS 137 13.2 AESCULAP, INC. – A B. BRAUN COMPANY 138 13.2.1 COMPANY SNAPSHOT 138 13.2.2 COMPANY SHARE ANALYSIS 138 13.2.3 PRODUCT PORTFOLIO 139 13.2.4 RECENT DEVELOPMENT 139 13.3 INTEGRA LIFESCIENCES 140 13.3.1 COMPANY SNAPSHOT 140 13.3.2 REVENUE ANALYSIS 140 13.3.3 COMPANY SHARE ANALYSIS 141 13.3.4 PRODUCT PORTFOLIO 141 13.3.5 RECENT DEVELOPMENT 142 13.4 SPIEGELBERG GMBH & CO. KG 143 13.4.1 COMPANY SNAPSHOT 143 13.4.2 COMPANY SHARE ANALYSIS 143 13.4.3 PRODUCT PORTFOLIO 144 13.4.4 RECENT DEVELOPMENT 144 13.5 BICAKCILAR 145 13.5.1 COMPANY SNAPSHOT 145 13.5.2 COMPANY SHARE ANALYSIS 145 13.5.3 PRODUCT PORTFOLIO 146 13.5.4 RECENT DEVELOPMENTS 146 13.6 ANUNCIA INC 147 13.6.1 COMPANY SNAPSHOT 147 13.6.2 PRODUCT PORTFOLIO 147 13.6.3 RECENT DEVELOPMENT 147 13.7 CHRISTOPH MIETHKE GMBH & CO. KG 148 13.7.1 COMPANY SNAPSHOT 148 13.7.2 PRODUCT PORTFOLIO 148 13.7.3 RECENT DEVELOPMENT 149 13.8 DESU MEDICAL 150 13.8.1 COMPANY SNAPSHOT 150 13.8.2 PRODUCT PORTFOLIO 150 13.8.3 RECENT DEVELOPMENT 150 13.9 G.SURGIWEAR LTD 151 13.9.1 COMPANY SNAPSHOT 151 13.9.2 PRODUCT PORTFOLIO 151 13.9.3 RECENT DEVELOPMENT 151 13.10 HPBIO 152 13.10.1 COMPANY SNAPSHOT 152 13.10.2 PRODUCT PORTFOLIO 152 13.10.3 RECENT DEVELOPMENT 152 13.11 KANEKA MEDIX CORP 153 13.11.1 COMPANY SNAPSHOT 153 13.11.2 REVENUE ANALYSIS 153 13.11.3 PRODUCT PORTFOLIO 155 13.11.4 RECENT DEVELOPMENTS 155 13.12 KARL STORZ SE & CO. KG 156 13.12.1 COMPANY SNAPSHOT 156 13.12.2 PRODUCT PORTFOLIO 156 13.12.3 RECENT DEVELOPMENT 156 13.13 MÖLLER MEDICAL GMBH 157 13.13.1 COMPANY SNAPSHOT 157 13.13.2 PRODUCT PORTFOLIO 157 13.13.3 RECENT DEVELOPMENT 157 13.14 NATUS MEDICAL INCORPORATED 158 13.14.1 COMPANY SNAPSHOT 158 13.14.2 PRODUCT PORTFOLIO 158 13.14.3 RECENT DEVELOPMENTS 159 13.15 SOPHYSA 160 13.15.1 COMPANY SNAPSHOT 160 13.15.2 PRODUCT PORTFOLIO 160 13.15.3 RECENT DEVELOPMENTS 161 14 QUESTIONNAIRE 162 15 RELATED REPORTS 165
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Data Bridge Market Research社の医療分野での最新刊レポート本レポートと同じKEY WORD(apac)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|